Curocell's RIMQARTO Inj. Wins Full Regulatory Approval, Poised to Enter CAR-T Market with 67% Complete Response Rate
Curocell (KOSDAQ: 372320) said that RIMQARTO® Inj. (anbalcabtagene autoleucel), South Korea’s first domestically developed CAR T-cell therapy, has secured full regulatory approval from the Ministry of Food and Drug Safety (MFDS) on April 29. With this approval, RIMQARTO® becomes the 42nd drug domestically developed under the Act on the Safety of and Support for Advanced Regenerative Medicine and Advanced Biological Products for manufacture and sale. This represents the first commercialization of CAR T-cell therapy by a Korean company.
